Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2...

Full description

Bibliographic Details
Main Authors:	Simpson, CR, Kerr, S, Katikireddi, SV, McCowan, C, Ritchie, LD, Pan, J, Stock, SJ, Rudan, I, Tsang, RSM, de Lusignan, S, Hobbs, FDR, Akbari, A, Lyons, RA, Robertson, C, Sheikh, A
Format:	Journal article
Language:	English
Published:	Springer Nature 2022

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Similar Items